<html><head>
<meta HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=windows-1252">
<meta NAME="GENERATOR" CONTENT="Microsoft FrontPage 3.0">
<title>The Dawn of a New Era</title>
</head>
<body LINK="#0000ff" VLINK="#800080" topmargin="0" leftmargin="0">
<font SIZE="2"><div align="left">
<table border="0" cellpadding="0" cellspacing="0" width="600" height="488">
<tr>
<td width="120"><img src="http://206.161.225.56/~vscan/mail/generex/images/blank.gif"
width="120" height="10"></td>
<td width="10"><img src="http://206.161.225.56/~vscan/mail/generex/images/blank.gif"
width="10" height="10"></td>
<td width="470"><img src="http://206.161.225.56/~vscan/mail/generex/images/blank.gif"
width="120" height="10"></td>
</tr> <tr>
<td width="120" bgcolor="#0000FF" valign="top" height="467"><font FACE="Arial" SIZE="2"
COLOR="#ffffff"><p align="center"><img
SRC="http://206.161.225.56/~vscan/mail/generex/images/generex.gif" border="0" hspace="5"
vspace="5" WIDTH="96" HEIGHT="99"></font><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/side_1.gif"
alt="Generex Biotechnology Corporation" vspace="8" WIDTH="90" HEIGHT="50"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/blue_dot.gif" width="10"
height="20" vspace><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/invest1.gif" alt="Call Now"
border="0" WIDTH="110" HEIGHT="60"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/blue_dot.gif" width="10"
height="20" vspace><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/s_corph.gif"
alt="Corporate Info" WIDTH="70" HEIGHT="36"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/s_corpi.gif" alt="Stock Info"
WIDTH="110" HEIGHT="160"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/blue_dot.gif" width="10"
height="20"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/s_conth.gif" alt="Contact Info"
WIDTH="70" HEIGHT="50"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/s_conti.gif"
alt="The Time Release Group" border="0" WIDTH="99" HEIGHT="70"><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/blue_dot.gif" width="3"
height="15"><br>
<a href="mailto:info at generex.com"><img
src="http://206.161.225.56/~vscan/mail/generex/images/info.gif" alt="Contact Us"
border="0" WIDTH="110" HEIGHT="19"></a><br>
<img src="http://206.161.225.56/~vscan/mail/generex/images/s_addr3.gif" alt="Address"
border="0" WIDTH="98" HEIGHT="57"><br>
<a href="mailto:unsubscribe at generex.com"><img
src="http://206.161.225.56/~vscan/mail/generex/images/remove.gif" alt="Unsubscrice"
border="0" vspace="10" WIDTH="110" HEIGHT="54"></a></font></td>
<td width="10" height="467"></td>
<td width="470" valign="top" height="656"><align="center"><big><img
src="http://206.161.225.56/~vscan/mail/generex/images/h_dawn.gif"
alt="The Dawn of a New Era" vspace="5" WIDTH="456" HEIGHT="35"></big><div align="center"><center><table
border="0" cellpadding="0" cellspacing="0" width="455">
<tr>
<td colspan="2"><img src="http://206.161.225.56/~vscan/mail/generex/images/h_rule.gif"
alt="h_rule.gif (979 bytes)" WIDTH="454" HEIGHT="15"></td>
</tr> <tr>
<td valign="top"><img src="http://206.161.225.56/~vscan/mail/generex/images/h_oral.gif"
alt="Oral" align="top" WIDTH="205" HEIGHT="60"></td>
<td valign="bottom"><img src="http://206.161.225.56/~vscan/mail/generex/images/h_insu.gif"
alt="Insulin" WIDTH="250" HEIGHT="90"></td>
</tr> <tr>
<td colspan="2"><img src="http://206.161.225.56/~vscan/mail/generex/images/h_rule.gif"
alt="h_rule.gif (979 bytes)" WIDTH="454" HEIGHT="15"></td>
</tr>
</table>
</center></div><font size="3"><p><font face="Arial" size="2" color="#000000"><strong>Generex
Biotechnology Corporation (GNBT)</strong></font><font face="Arial" size="2"> is set to
introduce a new way of life for diabetics. 135 million people are inflicted with diabetes
worldwide and that number is expected to double by the year 2025. In the United States
alone it is the second leading cause of death. It accounts for $135 billion in health care
costs and economic losses in 1997.</font></p>
<p></font><font face="Arial" size="2" color="#000000"><strong>GNBT's</strong></font><font
face="Arial" size="2"> patented drug delivery platform technologies to administer large
molecule drugs would allow diabetics a better quality of life without the use of needles.</font><font
size="3"></p>
<p></font><font face="Arial" size="2">The first application of the technology is </font><font
color="#0000FF" face="Arial" size="2"><strong>ORALIN</strong>™</font><font
face="Arial" size="2"> an oral insulin formulation designed to provide an alternative to
injected insulin in the treatment of diabetes.</font><font size="3"></p>
<p></font><font face="Arial" size="2">The company has conducted approximately 50 clinical
trials to evaluate the efficiency, dosage and safety of </font><font color="#0000FF"
face="Arial" size="2"><strong>ORALIN</strong>™</font><font face="Arial" size="2"> in
the treatment of diabetes. Those trials have provided encouraging evidence that </font><font
color="#0000FF" face="Arial" size="2"><strong>ORALIN</strong>™</font><font
face="Arial" size="2"> regulates glucose levels effectively. The results have received the
attention of the international pharmaceutical community, and the company is pursuing
"partnering", licensing and other commercial arrangements with a number of
multinational companies.</font><font size="3"></p>
<p><img src="http://206.161.225.56/~vscan/mail/generex/images/h_news.gif"
alt="News Release" WIDTH="186" HEIGHT="21"><br>
</font><font face="Arial" size="2">The company has sent out a press release announcing<strong>
Investigational New Drug ("IND")</strong> submission for </font><font
color="#0000FF" face="Arial" size="2"><strong>ORALIN</strong>™</font><font
face="Arial" size="2"> the company’s oral insulin formulation. The submission was
made with Canada’s <strong>Health Protection Branch ("HPB")</strong>. The <strong>IND</strong>
submission for </font><font color="#0000FF" face="Arial" size="2"><strong>ORALIN</strong>™</font><font
face="Arial" size="2"> provides for five Phase II, and two Phase III, clinical studies
designed to demonstrate the efficacy and safety of </font><font color="#0000FF"
face="Arial" size="2"><strong>ORALIN</strong>™</font><font face="Arial" size="2"> in
treating Type I and Type II diabetic patients. Initial Phase II studies will be conducted
with Type I (i.e., insulin dependent) diabetic patients at <strong>Mount Sinai Hospital in
Toronto</strong>. Study data will be analyzed at the <strong>Core Laboratory, Banting and
Best Diabetes Center</strong>. </font><font size="3"></p>
<p></font><font face="Arial" size="2">For more information, on </font><font
color="#0000FF" face="Arial" size="2"><strong>ORALIN</strong>™</font><font
face="Arial" size="2"> or <strong>Generex Biotechnology Corporation</strong> please call
us at <font color="#FF0000"><strong>1-800-391-6755</strong></font>. Call now!</font></td>
<font size="1">
</tr>
</table>
</div></font>
</body></html>
